Testing a blood marker to predict rejection after kidney transplant
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at a specific marker on immune cells (called CD45RC on T lymphocytes) to see if it can predict when a kidney transplant might reject. If you’re at lower immunologic risk, your blood tests could help doctors spot rejection risk earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 69 years old (inclusive).
- You are receiving care for your first kidney transplant.
- You are considered to have low immune (immunologic) risk for rejection.
- You can understand and complete consent paperwork in French.
- You must be able to sign informed consent in writing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving you back specially grown immune cells (called Tregs) made from your own blood can help your body accept a new kidney from a living donor with less rejection. It is for people who are ready for a first kidney transplant.
This study looks at special blood tests to help predict when kidney transplant rejection might happen. If the markers work, they could help doctors catch rejection earlier and adjust treatment sooner.
This trial is testing a new blood test (called TreaT-Assay) to help diagnose acute rejection after a kidney transplant. The goal is to catch rejection earlier and more accurately, so you can get the right treatment faster.
This study tests a new blood test (called cfDNA) that may help doctors detect early signs of kidney transplant rejection before problems develop. The goal is to help keep your transplanted kidney healthy longer by catching issues early.
This study is for people with a kidney transplant who are in the hospital for a biopsy because their doctor suspects rejection. Researchers want to see if a simple blood or urine test can detect rejection, which might make future biopsies less necessary.
This study looks for pieces of kidney DNA in the blood of people who have a kidney transplant and need a biopsy. The goal is to see if this test can help doctors know if the kidney is being rejected without needing a biopsy.
Hear when a new End Stage Renal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.